# Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma

Source: https://onco.cc/trials/nct07551349/  
OnCo record `nct07551349` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fludarabine in renal cell carcinoma, run by Beijing Biotech, now recruiting.

## Summary

Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT07551349 by Beijing Biotech, with 36 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: EB-701/CA9-NK, Fludarabine. Conditions listed: Advanced or Metastatic Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07551349
- Phase: 1/2
- Setting: An Open-Label, Multicenter, Phase 1/2 Study of Allogeneic Dual-target CD70/CAIX (CA9) Chimeric Antigen Receptor Natural Killer Cells in Adults With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Sponsor: Beijing Biotech
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07551349: https://clinicaltrials.gov/study/NCT07551349

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07551349.json